<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.1 20050630//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-5-134</article-id><article-id pub-id-type="pmid">16229746</article-id><article-id pub-id-type="doi">10.1186/1471-2407-5-134</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct <italic>BRCA1 </italic>founder mutations; relation to age at diagnosis and survival</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Kringen</surname><given-names>Pedro</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>pedrok@broadpark.no</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Wang</surname><given-names>Yun</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>yun.wang@medisin.uio.no</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Dumeaux</surname><given-names>Vanessa</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I5">5</xref><email>vanessa.dumeaux@medisin.uio.no</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Nesland</surname><given-names>Jahn M</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>j.m.nesland@medisin.uio.no</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Kristensen</surname><given-names>Gunnar</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>gunnar.kristensen@klinmed.uio.no</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Borresen-Dale</surname><given-names>Anne-Lise</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>a.l.borresen-dale@medisin.uio.no</email></contrib><contrib id="A7" corresp="yes" contrib-type="author"><name><surname>Dorum</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>anne.dorum@dnr.uio.no</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Genetics, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway</aff><aff id="I2"><label>2</label>Department of Gynecologic Oncology, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway</aff><aff id="I3"><label>3</label>University of Oslo, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway</aff><aff id="I4"><label>4</label>Department of Pathology, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway</aff><aff id="I5"><label>5</label>Institute of Community Medicine, University of Troms&#x000f8;</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>17</day><month>10</month><year>2005</year></pub-date><volume>5</volume><fpage>134</fpage><lpage>134</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/5/134"/><history><date date-type="received"><day>14</day><month>1</month><year>2005</year></date><date date-type="accepted"><day>17</day><month>10</month><year>2005</year></date></history><copyright-statement>Copyright &#x000a9; 2005 Kringen et al; licensee BioMed Central Ltd.</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><sec><title>Background</title><p>Ovarian carcinomas from 30 <italic>BRCA1 </italic>germ-line carriers of two distinct high penetrant founder mutations, 20 carrying the 1675delA and <bold>10 </bold>the 1135insA, and 100 sporadic cases were characterized for somatic mutations in the <italic>TP53 </italic>gene. We analyzed differences in relation to <italic>BRCA1 </italic>germline status, <italic>TP53 </italic>status, survival and age at diagnosis, as previous studies have not been conclusive.</p></sec><sec sec-type="methods"><title>Methods</title><p>DNA was extracted from paraffin embedded formalin fixed tissues for the familial cases, and from fresh frozen specimen from the sporadic cases. All cases were treated at our hospital according to protocol. Mutation analyses of exon 2 &#x02013; 11 were performed using TTGE, followed by sequencing.</p></sec><sec><title>Results</title><p>Survival rates for <italic>BRCA1</italic>-familial cases with <italic>TP53 </italic>mutations were not significantly lower than for familial cases without <italic>TP53 </italic>mutations (p = 0.25, RR = 1.64, 95% CI [0.71&#x02013;3.78]). Median age at diagnosis for sporadic (59 years) and familial (49 years) cases differed significantly (p &#x0003c; 0.001) with or without <italic>TP53 </italic>mutations. Age at diagnosis between the two types of familial carriers were not significantly different, with median age of 47 for 1675delA and 52.5 for 1135insA carriers (p = 0.245). For cases &#x02265;50 years at diagnosis, a trend toward longer survival for sporadic over familial cases was observed (p = 0.08). The opposite trend was observed for cases &#x0003c;50 years at diagnosis.</p></sec><sec><title>Conclusion</title><p>There do not seem to be a protective advantage for familial <italic>BRCA1 </italic>carriers without <italic>TP53 </italic>mutations over familial cases with <italic>TP53 </italic>mutations. However, there seem to be a trend towards initial advantage in survival for familial cases compared to sporadic cases diagnosed before the age of 50 both with and without <italic>TP53 </italic>mutations. However, this trend diminishes over time and for cases diagnosed &#x02265;50 years the sporadic cases show a trend towards an advantage in survival over familial cases. Although this data set is small, if confirmed, this may be a link in the evidence that the differences in ovarian cancer survival reported, are not due to the type of <italic>BRCA1 </italic>mutation, but may be secondary to genetic factors shared. This may have clinical implications for follow-up such as prophylactic surgery within carriers of the two most frequent Norwegian <italic>BRCA1 </italic>founder mutations.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Ovarian cancer is one of the leading causes of cancer-related death in women today. It is the 4<sup>th </sup>most common cancer in women in Norway and accounts for 5 &#x02013; 6% of all cancers [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Mean age at diagnosis for sporadic cases have been reported to 62.3 years [<xref ref-type="bibr" rid="B3">3</xref>], and in Norway to 65 years. Age-standardized incidence rates were 13.5 pr 100.000, and close to 40% of the patients is achieving 5-year survival according to The Norwegian Cancer Registry (OVANOR 1991 &#x02013; 1996).</p><p>Almost 10% of epithelial ovarian cancer cases are associated with dominant genetic predisposition, in most cases (80 &#x02013; 90%), linked to mutations in <italic>BRCA1 </italic>or <italic>BRCA2 </italic>[<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. Mean age at diagnosis for these inherited cases have been reported to be from 49 to 54.3 years [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. The penetrance of the disease in mutation carriers varies, and has been reported to be from 27 &#x02013; 80% [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. It should be noted that both the incidence rate for hereditary cases and the penetrance of the disease may differ depending on geographic and ethnic origin [<xref ref-type="bibr" rid="B11">11</xref>]. The survival rate may also vary depending on type and localization of the mutation. Some studies have reported that ovarian cancer patients carrying germ-line <italic>BRCA1 </italic>mutations have an enhanced survival rate compared to sporadic cases [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Other studies demonstrated only an initial survival advantage that disappeared with time, and concluded that no enhanced survival rates follows <italic>BRCA1 </italic>dysfunction [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. These studies predict a survival rate for <italic>BRCA1 </italic>familial ovarian cancer that is equal to or higher than non-familial cases.</p><p>Both the penetrance estimates and the survival rates are based on studies in populations with strong founder effects, and may therefore be biased. The type of mutation in the <italic>BRCA1 </italic>gene may affect the timing of the diagnosis of the disease, the response to environmental exposure causing DNA damage, the efficiency of DNA repair, and the frequency of somatic mutations developing in the tumor. These factors may in turn affect the survival rate.</p><p>Mutations in the <italic>TP53 </italic>tumor suppressor gene are the most common genetic alteration in human tumors and have been suggested as a molecular marker for prognosis. <italic>TP53 </italic>encodes a nuclear phosphoprotein located at chromosome region 17p13 involved in cell cycle arrest and DNA repair and somatic <italic>TP53 </italic>mutations are known to associate with familial ovarian cancer. In ovarian tumors from <italic>BRCA1 </italic>mutation carriers, somatic <italic>TP53 </italic>mutations are found in 60 &#x02013; 80% of the cases [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. Thirty to 50% of all ovarian cancers have been reported to harbor a <italic>TP53 </italic>mutation [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. Further, in 30 &#x02013; 85% of the sporadic ovarian carcinomas both a <italic>TP53 </italic>mutations and a somatic <italic>BRCA1/BRCA2 </italic>mutation have been found [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B25">25</xref>].</p><p>These findings implicate that <italic>TP53 </italic>and <italic>BRCA1 </italic>directly interacts and may play an important role in DNA repair processes and tumor suppression [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. However, despite the high frequency of mutations in the tumor suppressor gene <italic>TP53</italic>, there are several reports concluding that <italic>TP53 </italic>is not a good predictor of prognosis in sporadic ovarian cancer patients [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>].</p><p>We have previously reported two Norwegian <italic>BRCA1 </italic>founder mutations; 1135insA [<xref ref-type="bibr" rid="B30">30</xref>] and 1675delA [<xref ref-type="bibr" rid="B11">11</xref>]. Carriers of these mutations show almost the same penetrance for ovarian- and breast cancer and the penetrance is also high compared to most reported <italic>BRCA1 </italic>mutation carriers. By age 50, 48% of mutation carriers had experienced breast- and/or ovarian cancer. Mean age of ovarian cancer diagnosis was ~55 years [<xref ref-type="bibr" rid="B10">10</xref>]. Three per cent of all Norwegian ovarian cancers are caused by either of the two founder mutations [<xref ref-type="bibr" rid="B31">31</xref>]. As a result of a clinical follow-up program for early diagnosis in women from breast-ovarian cancer kindreds, these two mutations may account for more than half of those with a <italic>BRCA1 </italic>mutation in Norway. The histopathological characteristics of both breast and ovarian cancer indicated an unfavorable prognosis in these mutation carriers [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>In the present study, we have screened epithelial ovarian tumors from 30 familial cases and 100 sporadic cases for somatic mutations in the <italic>TP53 </italic>gene. The cancer treatment was according to our hospital protocol. The familial cases consisted of one group with the <italic>BRCA1 </italic>1135insA mutation and the other had the <italic>BRCA1 </italic>1675delA mutation [<xref ref-type="bibr" rid="B10">10</xref>]. The <italic>TP53 </italic>mutation status was correlated to survival, age at diagnosis and histopathological features.</p></sec><sec sec-type="materials"><title>Materials</title><p>Formalin fixed and paraffin embedded ovarian cancer tissue from 30 <italic>BRCA1 </italic>germ line mutation carriers were collected and used for DNA extraction. Of the familial cases 20 patients carried the 1675delA mutation and another 10 patients the 1135insA mutation, which is a representative distribution between the two mutations in the Norwegian population. The <italic>BRCA1 </italic>carriers were from families with at least two first-degree relatives, or second-degree relatives through male, with ovarian cancer and/or breast cancer under age 60. All cases were sampled from pedigree regardless of survival status, as ovarian cancer treatment is centralized to our hospital. Analysis of fresh frozen specimen of tumor DNA from the 100 sporadic cases sampled from 1992&#x02013;2003, included in this study has previously been reported [<xref ref-type="bibr" rid="B29">29</xref>]. Both groups were diagnosed and treated at the Norwegian Radium Hospital according to protocol. The patient characteristics are shown in Table <xref ref-type="table" rid="T1">1</xref>. All tumors were reviewed at our department of pathology, the familial tumors by our team pathologist, and were classified and graded according to the World Health Organization (WHO) criteria. Follow-up time for each case was calculated from the date of diagnosis up to date of death or end of study (15<sup>th </sup>April, 2004).</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>DNA extraction and <italic>TP53 </italic>mutation analysis</title><p>DNA was manually extracted from paraffin-embedded tissue sections of tumor material using 5 sections of 10 &#x003bc;. A modification of the procedure described by Miller [<xref ref-type="bibr" rid="B33">33</xref>] was used. The modification included using as much as possible of the top water layer of the 700 ml DNA/lysis buffer and 1 ml phenol/chloroform/water mix, and repeating the extraction step once. The protocol was optimized to give high yield of good quality DNA.</p><p>Mutation analyses of exons 2&#x02013;11 of the <italic>TP53 </italic>gene in the 30 cases with <italic>BRCA1 </italic>germ line mutations were performed by TTGE followed by sequencing. Primers, PCR conditions and gel running conditions were as described elsewhere [<xref ref-type="bibr" rid="B34">34</xref>]. Samples with aberrantly migrating bands on TTGE were isolated, submitted to a new PCR and sequenced. Analysis of the fresh frozen specimen of tumor DNA from the 100 sporadic cases has previously been reported [<xref ref-type="bibr" rid="B29">29</xref>].</p></sec><sec><title>Statistical analyses</title><p>In univariate analyses, a log rank test have been used to investigate the effect of age at diagnosis, <italic>BRCA1 </italic>and <italic>TP53 </italic>mutations on the survival rate. In multivariate analyses, Cox proportional hazards regression analysis was used. Hazard ratios (HR's) are given with 95% confidence intervals (CI's). Statistical significance rates were set at 0.05. The software SAS<sup>&#x000ae; </sup>version 8.2 was used for statistical analyses.</p></sec></sec><sec><title>Results</title><sec><title><italic>TP53 </italic>characterizations and novel mutations</title><p>Nineteen of the 30 ovarian carcinomas showed one or more aberrant migrating bands on TTGE in one or more exons and was sequenced (Table <xref ref-type="table" rid="T2">2</xref>). A total of 21 sequence changes were detected. Two cases had two different <italic>TP53 </italic>sequence changes in their tumors, one being a silent mutation. Nine mutations were missense mutations, four nonsense, three were silent sequence changes (not previously reported as polymorphisms) and two were intronic sequence changes of unknown function.</p><p>The frequency of transitions vs. transversion in this hereditary cohort (85.7% and 14.3%) was also quite similar to that reported in the IARC database for sporadic cases (88% and 12%), but differed slightly from the sporadic cases in this study (76.4% and 23.6%). The frequency of mutations likely to cause protein alteration were 68.0% (68/100) for the sporadic cases and 53.3%(16/30) for the familial cases. The <italic>TP53 </italic>mutation frequency in the two different <italic>BRCA1 </italic>carriers differed slightly with 11/20 (55.0%) in the <italic>BRCA1 </italic>1675delA carriers and 5/10 (50.0%) in the <italic>BRCA1 </italic>1135insA carriers. The 1675delA carriers had 7.7% transversions and 92.3% transitions while the 1135insA carriers had 12.5% transversion and 82.5% transitions. Four of the <italic>TP53 </italic>mutations were novel and not previously reported in ovarian cancer in the IARC <italic>TP53 </italic>Database [<xref ref-type="bibr" rid="B35">35</xref>] or the SOUSSI database. These mutations affected codon 205 (tyr&#x0003e;ser), 260 (ser&#x0003e;ser), 267 (arg&#x0003e;gln) and 293 (gly&#x0003e;arg). All mutations detected resided in exons 5&#x02013;8. When comparing the <italic>TP53 </italic>mutation spectrum in these familial cases with that of ovarian cancers cases reported in the IARC database and to the 100 sporadic ovarian cancer cases with a <italic>TP53 </italic>mutation, no obvious differences were seen either with respect to exon distribution or codon wise (data not shown), although a slightly lower frequency of mutations in exon 5 and a slightly higher in exon 8 were seen in the hereditary cases. The <italic>TP53 </italic>mutations in the 100 sporadic cases used in this study is reported elsewhere [<xref ref-type="bibr" rid="B29">29</xref>].</p></sec><sec><title>Age at diagnosis, survival, <italic>BRCA1 </italic>and <italic>TP53 </italic>status</title><p>Median age at diagnosis among sporadic cases and familial cases that carried 1675delA or 1135insA mutations is presented in Table <xref ref-type="table" rid="T1">1</xref>. As expected, the familial cases are diagnosed earlier in life than sporadic cases (p &#x0003c; 0.001). The difference in median age of onset between the 1135insA and 1675delA mutation carriers was not significant (p = 0.245).</p><p>In the univariate analysis of the combined group, neither <italic>BRCA1 </italic>status nor age at diagnosis was significantly associated to survival (p = 0.87 and p = 0.50 for <italic>BRCA1 </italic>status and age at diagnosis (categorized into &#x0003c; 50 and &#x02265; 50 years), respectively). <italic>TP53 </italic>mutation did not significantly reduce the survival rates (p = 0.35). Notably, interaction between <italic>BRCA1 </italic>status and <italic>TP53 </italic>status was borderline significant (test for interaction: p = 0.06) while the one between <italic>BRCA1 </italic>status and age at diagnosis was statistically significant (test for interaction: p = 0.05). We further analyzed these factors adjusted for tumor grade, however, results did not substantially change (test interaction: p = 0.04 and p = 0.05 for BRCA1*TP53 and BRCA1*age at diagnosis, respectively).</p><p>No association between age at diagnosis and survival time was found among sporadic cases (p = 0.88). Familial cases with late age at diagnosis (&#x02265;50 years) had a slightly higher risk of dying than the cases with an early age at diagnosis, however the association did not reach significance, possibly due to a lack of statistical power (RR = 1.65, 95% CI [0.79&#x02013;3.43], p = 0.14). Among cases diagnosed at age 50 years or more, familial cases had a trend towards a higher risk of dying than sporadic cases (RR = 1.75, 95% CI [0.93&#x02013;3.30], p = 0.08). After adjustment for the effect of tumor grade and <italic>TP53 </italic>status (RR = 1.80, 95% CI [0.94&#x02013;3.43], p = 0.08) (data not shown). Table <xref ref-type="table" rid="T3">3</xref> shows the risk ratios associated to <italic>TP53 </italic>mutations after stratification for <italic>BRCA1 </italic>status.</p><p>There was no significant difference in survival observed among <italic>TP53 </italic>mutations carriers compared to non-<italic>TP53 </italic>mutations carriers, neither for the familial nor the sporadic cases (Log-rank test for <italic>TP53 </italic>in familial cases: p = 0.25 and log-rank test for <italic>TP53 </italic>in sporadic cases: p = 0.88) (Table <xref ref-type="table" rid="T3">3</xref>).</p></sec></sec><sec><title>Discussion</title><p>Some studies have reported an enhanced survival for <italic>BRCA1 </italic>carriers with ovarian cancer compared to sporadic cases [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>], but these studies have not taken <italic>TP53 </italic>status in the tumors in to consideration. Other studies in which <italic>TP53 </italic>status have been included concludes that there is no difference in survival [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>Our results do not show an enhanced survival rate for familial cases compared to sporadic cases, even after adjustment for <italic>TP53 </italic>status when all age groups were included. Further, no significant difference in survival rates was observed between the familial cases with and without <italic>TP53 </italic>mutations (Table <xref ref-type="table" rid="T3">3</xref>).</p><p>These results <bold>do not </bold>support earlier observations regarding the importance of the p53/BRCA1 interaction on cell proliferation and ovarian carcinogenesis. Most penetrance estimates and survival rates are based on studies in populations with strong founder effects, and may therefore be biased [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B38">38</xref>]. Two Ashkenazi founder mutations occur in <italic>BRCA1 </italic>185delAG and 5382insC (carrier frequencies of 0.9% and 0.13%), with mean age at diagnosis 54 years. How the type of mutation in the <italic>BRCA1 </italic>gene affects survival, age at diagnosis of the disease, the response to environmental exposure causing DNA damage, and the efficiency of DNA repair, is not clarified. Heterozygote advantage or an increase in biological fitness conferred on carriers of a disease causing mutation (like <italic>BRCA1</italic>?), often a resistance to certain infections that were common in times past, can cause an increase in allele frequency [<xref ref-type="bibr" rid="B39">39</xref>]. Genetic factors with impact on survival and age at onset of disease, to after childbearing age, would be preferential.</p><p>The trend for an increased survival in favour of the early age at onset in familial cases compared to late age at onset in familial cases may be attributed to younger patients having greater physical strength, less somatic mutations, and manage illness better than older patients. On the other hand, one might also expect this trend in sporadic cases, which was not the case. One limitation of our study is the small numbers of <italic>BRCA1 </italic>carriers. In our study, the statistical power to detect <italic>BRCA1 </italic>effect was 76%.</p><p>Consequently, our findings should be confirmed in larger studies. The conflicting literature on the impact of <italic>BRCA1 </italic>mutation status on ovarian cancer survival should promote additional studies from different ethnic populations, and thereby allow investigators to study whether or not there is a survival benefit due to <italic>BRCA1 </italic>mutation, or may be secondary to other common inherited genetic factors, which may be shared in ethnic or geographic isolated populations.</p><p>Alterations in the <italic>TP53 </italic>gene have been shown to affect breast cancer survival and in particular patients with mutations in the zinc-binding domains have poor survival [<xref ref-type="bibr" rid="B40">40</xref>]. In sporadic ovarian carcinoma several studies reports that no or little effect of <italic>TP53 </italic>mutations have been seen [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B28">28</xref>], which is similar to the results reported here. <italic>TP53 </italic>alterations are also suggested to alter ovarian cancer survival in <italic>BRCA1 </italic>germ line patients [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>], while other groups concludes with a failure of <italic>BRCA1 </italic>dysfunction to alter ovarian cancer survival [<xref ref-type="bibr" rid="B16">16</xref>]. It should also be noted that a considerable fraction (60&#x02013;80%) of all familial <italic>BRCA1 </italic>ovarian cancers harbor <italic>TP53 </italic>mutations [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. Only a few studies have reported analysis of <italic>TP53 </italic>mutations in relation to <italic>BRCA1 </italic>associated ovarian cancer [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B41">41</xref>]. The present study is the first investigating somatic <italic>TP53 </italic>mutations in ovarian tumors from carries of two distinct high penetrant <italic>BRCA1 </italic>germ-line mutations, relating it to survival and age at diagnosis of disease and compares it to sporadic cases. We have previously studied the distribution in age at diagnosis in <italic>BRCA1 </italic>carriers and non-carriers as a part of a cohort study. Three percent of Norwegian ovarian cancers are caused by <italic>BRCA1 </italic>1675delA or 1135insA [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B42">42</xref>], with a distribution similar to that found in this study (Table <xref ref-type="table" rid="T1">1</xref>). Further, Bj&#x000f8;rge et al. [<xref ref-type="bibr" rid="B43">43</xref>] found that 87.0% of Norwegian sporadic ovarian cancers was papillary serous adenocarcinoma, an aggressive histo-prognostic factor.</p><p>Eigthy percent of both familial and sporadic ovarian cancer cases in this study were papillary serous adenocarcinoma. Questions need to be addressed concerning the clinical effects of mutations in the <italic>BRCA1 </italic>gene, why some mutation carriers develop breast cancer, others develop ovarian cancer, and some develop both. We do not know whether the cancers occurring in mutation carriers are significantly different from those occurring in non carriers. The frequency of <italic>TP53 </italic>mutations in the familial cases altering the protein was 53.3%, which is somewhat higher than other studies of familial <italic>BRCA1 </italic>ovarian cancer (31&#x02013;50%) [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Although the number of familial cases in this study is limited, a slightly higher frequency of mutations was found in exon 8 and a lower frequency in exon 5 compared to sporadic cases in the IARC database. The same tendency has been reported by others [<xref ref-type="bibr" rid="B20">20</xref>]. However, a non-significant difference in <italic>TP53 </italic>mutation frequency was observed between the familial and sporadic cases in this study.</p><p>Of the novel mutations found in the familial cohort the codon 205 mutation has previously been reported in several other tumors like head and neck SCC as well as breast- and colorectal carcinoma. The amino acid change in codon 255 and 293 are only reported once, in oesophageal SCC and bladder cancer, respectively. The silent codon 260 mutation are reported in two different cancer tissues; lung (SCLC) and colorectal carcinoma. Environmental exposure, both external and internal, is known to influence the spectrum of mutations. Whether hormonal disturbance may affect the mutation rate and spectrum is not known, but if so, it may be expected that <italic>BRCA1 </italic>carriers are more sensitive to such exposure.</p></sec><sec><title>Conclusion</title><p>Interestingly, no difference in survival was observed between <italic>TP53 </italic>mutation carriers among the familial carries or among the sporadic cases (Table <xref ref-type="table" rid="T3">3</xref>). Further, we did not find an overall difference in survival between familial <italic>BRCA1 </italic>carriers and sporadic epithelial ovarian cancer cases, even after adjustment for <italic>TP53 </italic>status. For cases diagnosed over the age 50 there was a trend toward higher survival for sporadic cases.</p></sec><sec><title>List of abbreviations</title><p>TTGE; temporal temperature gradient gel electrophoresis; PCR, polymerase chain reaction; FIGO, International Federation of Gynaecology and Obstetrics. RR; risk ratio.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>PK participated in the design of the study, carried out the molecular genetic studies, sequence alignment and drafted the manuscript. YW participated in screening of the sporadic cases and sequence alignment. VD performed the statistical analyses. GK performed clinical updates of sporadic cases.</p><p>JMN evaluated pathology sections of sporadic and familial cases. ALBD conceived the study, participated in its design and helped draft the manuscript. AD conceived the study, performed clinical dates of the familial cases and helped draft the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/5/134/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>Pedro Kringen is a research fellow of The Norwegian Cancer Society. Guro Elisabeth Lind is acknowledged for working out the optimal condition for DNA extraction from paraffin embedded tissues. We thank Sigrid Lystad and Phuong Vu for providing excellent technical assistance.</p><p>This work was supported by grants from The Norwegian Cancer Society and The Norwegian Research Council.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="other"><person-group person-group-type="author"><collab>The Norwegian Cancer Registry</collab></person-group><article-title>Cancer in Norway 1998.</article-title><source>The Cancer Registry of Norway</source><ext-link ext-link-type="uri" xlink:href="http://www.kreftregisteret.no/"/></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Engeland</surname><given-names>A</given-names></name><name><surname>Haldorsen</surname><given-names>T</given-names></name><name><surname>Tretli</surname><given-names>S</given-names></name><name><surname>Hakulinen</surname><given-names>T</given-names></name><name><surname>Horte</surname><given-names>LG</given-names></name><name><surname>Luostarinen</surname><given-names>T</given-names></name><name><surname>Magnus</surname><given-names>K</given-names></name><name><surname>Schou</surname><given-names>G</given-names></name><name><surname>Sigvaldason</surname><given-names>H</given-names></name><name><surname>Storm</surname><given-names>HH</given-names></name><etal></etal></person-group><article-title>Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. A collaborative study of the five Nordic Cancer Registries</article-title><source>APMIS Suppl</source><year>1993</year><volume>38</volume><fpage>1</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">8297639</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zweemer</surname><given-names>RP</given-names></name><name><surname>Verheijen</surname><given-names>RH</given-names></name><name><surname>Menko</surname><given-names>FH</given-names></name><name><surname>Gille</surname><given-names>JJ</given-names></name><name><surname>van Diest</surname><given-names>PJ</given-names></name><name><surname>Coebergh</surname><given-names>JW</given-names></name><name><surname>Shaw</surname><given-names>PA</given-names></name><name><surname>Jacobs</surname><given-names>IJ</given-names></name><name><surname>Kenemans</surname><given-names>P</given-names></name></person-group><article-title>Differences between hereditary and sporadic ovarian cancer</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>1999</year><volume>82</volume><fpage>151</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">10206407</pub-id><pub-id pub-id-type="doi">10.1016/S0301-2115(98)00218-8</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miki</surname><given-names>Y</given-names></name><name><surname>Swensen</surname><given-names>J</given-names></name><name><surname>Shattuck-Eidens</surname><given-names>D</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Harshman</surname><given-names>K</given-names></name><name><surname>Tavtigian</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Cochran</surname><given-names>C</given-names></name><name><surname>Bennett</surname><given-names>LM</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1</article-title><source>Science</source><year>1994</year><volume>266</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">7545954</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Bignell</surname><given-names>G</given-names></name><name><surname>Lancaster</surname><given-names>J</given-names></name><name><surname>Swift</surname><given-names>S</given-names></name><name><surname>Seal</surname><given-names>S</given-names></name><name><surname>Mangion</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>N</given-names></name><name><surname>Gregory</surname><given-names>S</given-names></name><name><surname>Gumbs</surname><given-names>C</given-names></name><name><surname>Micklem</surname><given-names>G</given-names></name></person-group><article-title>Identification of the breast cancer susceptibility gene BRCA2</article-title><source>Nature</source><year>1995</year><volume>378</volume><fpage>789</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">8524414</pub-id><pub-id pub-id-type="doi">10.1038/378789a0</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boyd</surname><given-names>J</given-names></name></person-group><article-title>Molecular genetics of hereditary ovarian cancer</article-title><source>Oncology (Huntingt)</source><year>1998</year><volume>12</volume><fpage>399</fpage><lpage>406; discussion 409-10, 413</lpage></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>HT</given-names></name><name><surname>Watson</surname><given-names>P</given-names></name><name><surname>Lynch</surname><given-names>JF</given-names></name><name><surname>Conway</surname><given-names>TA</given-names></name><name><surname>Fili</surname><given-names>M</given-names></name></person-group><article-title>Hereditary ovarian cancer. Heterogeneity in age at onset</article-title><source>Cancer</source><year>1993</year><volume>71</volume><fpage>573</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">8420679</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>D</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Peto</surname><given-names>J</given-names></name></person-group><article-title>Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence</article-title><source>Am J Hum Genet</source><year>1995</year><volume>57</volume><fpage>1457</fpage><lpage>1462</lpage><pub-id pub-id-type="pmid">8533776</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>D</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Stratton</surname><given-names>M</given-names></name><name><surname>Narod</surname><given-names>S</given-names></name><name><surname>Goldgar</surname><given-names>D</given-names></name><name><surname>Devilee</surname><given-names>P</given-names></name><name><surname>Bishop</surname><given-names>DT</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Lenoir</surname><given-names>G</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name><name><surname>Sobol</surname><given-names>H</given-names></name><name><surname>Teare</surname><given-names>MD</given-names></name><name><surname>Struewing</surname><given-names>J</given-names></name><name><surname>Arason</surname><given-names>A</given-names></name><name><surname>Scherneck</surname><given-names>S</given-names></name><name><surname>Peto</surname><given-names>J</given-names></name><name><surname>Rebbeck</surname><given-names>TR</given-names></name><name><surname>Tonin</surname><given-names>P</given-names></name><name><surname>Neuhausen</surname><given-names>S</given-names></name><name><surname>Barkardottir</surname><given-names>R</given-names></name><name><surname>Eyfjord</surname><given-names>J</given-names></name><name><surname>Lynch</surname><given-names>H</given-names></name><name><surname>Ponder</surname><given-names>BA</given-names></name><name><surname>Gayther</surname><given-names>SA</given-names></name><name><surname>Zelada-Hedman</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium</article-title><source>Am J Hum Genet</source><year>1998</year><volume>62</volume><fpage>676</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">9497246</pub-id><pub-id pub-id-type="doi">10.1086/301749</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorum</surname><given-names>A</given-names></name><name><surname>Heimdal</surname><given-names>K</given-names></name><name><surname>Hovig</surname><given-names>E</given-names></name><name><surname>Inganas</surname><given-names>M</given-names></name><name><surname>Moller</surname><given-names>P</given-names></name></person-group><article-title>Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer</article-title><source>Am J Hum Genet</source><year>1999</year><volume>65</volume><fpage>671</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">10441573</pub-id><pub-id pub-id-type="doi">10.1086/302530</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorum</surname><given-names>A</given-names></name><name><surname>Moller</surname><given-names>P</given-names></name><name><surname>Kamsteeg</surname><given-names>EJ</given-names></name><name><surname>Scheffer</surname><given-names>H</given-names></name><name><surname>Burton</surname><given-names>M</given-names></name><name><surname>Heimdal</surname><given-names>KR</given-names></name><name><surname>Maehle</surname><given-names>LO</given-names></name><name><surname>Hovig</surname><given-names>E</given-names></name><name><surname>Trope</surname><given-names>CG</given-names></name><name><surname>van der Hout</surname><given-names>AH</given-names></name><name><surname>van der Meulen</surname><given-names>MA</given-names></name><name><surname>Buys</surname><given-names>CH</given-names></name><name><surname>te Meerman</surname><given-names>GJ</given-names></name></person-group><article-title>A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing</article-title><source>Eur J Cancer</source><year>1997</year><volume>33</volume><fpage>2390</fpage><lpage>2392</lpage><pub-id pub-id-type="pmid">9616287</pub-id><pub-id pub-id-type="doi">10.1016/S0959-8049(97)00328-6</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>SC</given-names></name><name><surname>Benjamin</surname><given-names>I</given-names></name><name><surname>Behbakht</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Morgan</surname><given-names>MA</given-names></name><name><surname>LiVolsi</surname><given-names>VA</given-names></name><name><surname>Berchuck</surname><given-names>A</given-names></name><name><surname>Muto</surname><given-names>MG</given-names></name><name><surname>Garber</surname><given-names>JE</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Lynch</surname><given-names>HT</given-names></name><name><surname>Boyd</surname><given-names>J</given-names></name></person-group><article-title>Clinical and pathological features of ovarian cancer in women with germ- line mutations of BRCA1</article-title><source>N Engl J Med</source><year>1996</year><volume>335</volume><fpage>1413</fpage><lpage>1416</lpage><pub-id pub-id-type="pmid">8875917</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199611073351901</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ben David</surname><given-names>Y</given-names></name><name><surname>Chetrit</surname><given-names>A</given-names></name><name><surname>Hirsh-Yechezkel</surname><given-names>G</given-names></name><name><surname>Friedman</surname><given-names>E</given-names></name><name><surname>Beck</surname><given-names>BD</given-names></name><name><surname>Beller</surname><given-names>U</given-names></name><name><surname>Ben-Baruch</surname><given-names>G</given-names></name><name><surname>Fishman</surname><given-names>A</given-names></name><name><surname>Levavi</surname><given-names>H</given-names></name><name><surname>Lubin</surname><given-names>F</given-names></name><name><surname>Menczer</surname><given-names>J</given-names></name><name><surname>Piura</surname><given-names>B</given-names></name><name><surname>Struewing</surname><given-names>JP</given-names></name><name><surname>Modan</surname><given-names>B</given-names></name></person-group><article-title>Effect of BRCA mutations on the length of survival in epithelial ovarian tumors</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>463</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">11786575</pub-id><pub-id pub-id-type="doi">10.1200/JCO.20.2.463</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cass</surname><given-names>I</given-names></name><name><surname>Baldwin</surname><given-names>RL</given-names></name><name><surname>Varkey</surname><given-names>T</given-names></name><name><surname>Moslehi</surname><given-names>R</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name><name><surname>Karlan</surname><given-names>BY</given-names></name></person-group><article-title>Improved survival in women with BRCA-associated ovarian carcinoma</article-title><source>Cancer</source><year>2003</year><volume>97</volume><fpage>2187</fpage><lpage>2195</lpage><pub-id pub-id-type="pmid">12712470</pub-id><pub-id pub-id-type="doi">10.1002/cncr.11310</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johannsson</surname><given-names>OT</given-names></name><name><surname>Ranstam</surname><given-names>J</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Olsson</surname><given-names>H</given-names></name></person-group><article-title>Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">9469321</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buller</surname><given-names>RE</given-names></name><name><surname>Shahin</surname><given-names>MS</given-names></name><name><surname>Geisler</surname><given-names>JP</given-names></name><name><surname>Zogg</surname><given-names>M</given-names></name><name><surname>De Young</surname><given-names>BR</given-names></name><name><surname>Davis</surname><given-names>CS</given-names></name></person-group><article-title>Failure of BRCA1 dysfunction to alter ovarian cancer survival</article-title><source>Clin Cancer Res</source><year>2002</year><volume>8</volume><fpage>1196</fpage><lpage>1202</lpage><pub-id pub-id-type="pmid">12006538</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith-Sorensen</surname><given-names>B</given-names></name><name><surname>Kaern</surname><given-names>J</given-names></name><name><surname>Holm</surname><given-names>R</given-names></name><name><surname>Dorum</surname><given-names>A</given-names></name><name><surname>Trope</surname><given-names>C</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name></person-group><article-title>Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status</article-title><source>Br J Cancer</source><year>1998</year><volume>78</volume><fpage>375</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">9703286</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramus</surname><given-names>SJ</given-names></name><name><surname>Bobrow</surname><given-names>LG</given-names></name><name><surname>Pharoah</surname><given-names>PD</given-names></name><name><surname>Finnigan</surname><given-names>DS</given-names></name><name><surname>Fishman</surname><given-names>A</given-names></name><name><surname>Altaras</surname><given-names>M</given-names></name><name><surname>Harrington</surname><given-names>PA</given-names></name><name><surname>Gayther</surname><given-names>SA</given-names></name><name><surname>Ponder</surname><given-names>BA</given-names></name><name><surname>Friedman</surname><given-names>LS</given-names></name></person-group><article-title>Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours</article-title><source>Genes Chromosomes Cancer</source><year>1999</year><volume>25</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">10337991</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1098-2264(199906)25:2&#x0003c;91::AID-GCC3&#x0003e;3.0.CO;2-5</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tworek</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>R</given-names></name><name><surname>Fetzer</surname><given-names>S</given-names></name><name><surname>Werness</surname><given-names>BA</given-names></name><name><surname>Piver</surname><given-names>MS</given-names></name><name><surname>Allen</surname><given-names>HJ</given-names></name><name><surname>DiCioccio</surname><given-names>RA</given-names></name></person-group><article-title>Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors</article-title><source>Cancer Genet Cytogenet</source><year>1999</year><volume>112</volume><fpage>105</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">10686936</pub-id><pub-id pub-id-type="doi">10.1016/S0165-4608(98)00267-2</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buller</surname><given-names>RE</given-names></name><name><surname>Lallas</surname><given-names>TA</given-names></name><name><surname>Shahin</surname><given-names>MS</given-names></name><name><surname>Sood</surname><given-names>AK</given-names></name><name><surname>Hatterman-Zogg</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>B</given-names></name><name><surname>Sorosky</surname><given-names>JI</given-names></name><name><surname>Kirby</surname><given-names>PA</given-names></name></person-group><article-title>The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer</article-title><source>Clin Cancer Res</source><year>2001</year><volume>7</volume><fpage>831</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">11309330</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhei</surname><given-names>E</given-names></name><name><surname>Bogomolniy</surname><given-names>F</given-names></name><name><surname>Federici</surname><given-names>MG</given-names></name><name><surname>Maresco</surname><given-names>DL</given-names></name><name><surname>Offit</surname><given-names>K</given-names></name><name><surname>Robson</surname><given-names>ME</given-names></name><name><surname>Saigo</surname><given-names>PE</given-names></name><name><surname>Boyd</surname><given-names>J</given-names></name></person-group><article-title>Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>3193</fpage><lpage>3196</lpage><pub-id pub-id-type="pmid">9699640</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schorge</surname><given-names>JO</given-names></name><name><surname>Muto</surname><given-names>MG</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Huang</surname><given-names>LW</given-names></name><name><surname>Welch</surname><given-names>WR</given-names></name><name><surname>Bell</surname><given-names>DA</given-names></name><name><surname>Keung</surname><given-names>EZ</given-names></name><name><surname>Berkowitz</surname><given-names>RS</given-names></name><name><surname>Mok</surname><given-names>SC</given-names></name></person-group><article-title>BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>1361</fpage><lpage>1364</lpage><pub-id pub-id-type="pmid">10728699</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wertheim</surname><given-names>I</given-names></name><name><surname>Muto</surname><given-names>MG</given-names></name><name><surname>Welch</surname><given-names>WR</given-names></name><name><surname>Bell</surname><given-names>DA</given-names></name><name><surname>Berkowitz</surname><given-names>RS</given-names></name><name><surname>Mok</surname><given-names>SC</given-names></name></person-group><article-title>p53 gene mutation in human borderline epithelial ovarian tumors</article-title><source>J Natl Cancer Inst</source><year>1994</year><volume>86</volume><fpage>1549</fpage><lpage>1551</lpage><pub-id pub-id-type="pmid">7932812</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fallows</surname><given-names>S</given-names></name><name><surname>Price</surname><given-names>J</given-names></name><name><surname>Atkinson</surname><given-names>RJ</given-names></name><name><surname>Johnston</surname><given-names>PG</given-names></name><name><surname>Hickey</surname><given-names>I</given-names></name><name><surname>Russell</surname><given-names>SE</given-names></name></person-group><article-title>P53 mutation does not affect prognosis in ovarian epithelial malignancies</article-title><source>J Pathol</source><year>2001</year><volume>194</volume><fpage>68</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">11329143</pub-id><pub-id pub-id-type="doi">10.1002/path.857</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozalp</surname><given-names>S</given-names></name><name><surname>Yalcin</surname><given-names>OT</given-names></name><name><surname>Minsin</surname><given-names>TH</given-names></name></person-group><article-title>Expression of p53 in epithelial ovarian cancer</article-title><source>Int J Gynaecol Obstet</source><year>2000</year><volume>71</volume><fpage>277</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">11102625</pub-id><pub-id pub-id-type="doi">10.1016/S0020-7292(00)00309-X</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>T</given-names></name><name><surname>Chapman</surname><given-names>DL</given-names></name><name><surname>Papaioannou</surname><given-names>VE</given-names></name><name><surname>Efstratiadis</surname><given-names>A</given-names></name></person-group><article-title>Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos</article-title><source>Genes Dev</source><year>1997</year><volume>11</volume><fpage>1226</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">9171368</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sourvinos</surname><given-names>G</given-names></name><name><surname>Spandidos</surname><given-names>DA</given-names></name></person-group><article-title>Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors</article-title><source>Biochem Biophys Res Commun</source><year>1998</year><volume>245</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">9535786</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1998.8379</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Helland</surname><given-names>A</given-names></name><name><surname>Holm</surname><given-names>R</given-names></name><name><surname>Skomedal</surname><given-names>H</given-names></name><name><surname>Abeler</surname><given-names>VM</given-names></name><name><surname>Danielsen</surname><given-names>HE</given-names></name><name><surname>Trope</surname><given-names>CG</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name><name><surname>Kristensen</surname><given-names>GB</given-names></name></person-group><article-title>TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival</article-title><source>Br J Cancer</source><year>2004</year><volume>90</volume><fpage>678</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">14760384</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6601537</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kringen</surname><given-names>P</given-names></name><name><surname>Kristensen</surname><given-names>GB</given-names></name><name><surname>Holm</surname><given-names>R</given-names></name><name><surname>Baekelandt</surname><given-names>MM</given-names></name><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Skomedal</surname><given-names>H</given-names></name><name><surname>Hainaut</surname><given-names>P</given-names></name><name><surname>Trope</surname><given-names>CG</given-names></name><name><surname>Abeler</surname><given-names>VM</given-names></name><name><surname>Nesland</surname><given-names>JM</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name><name><surname>Helland</surname><given-names>A</given-names></name></person-group><article-title>Effect of the codon 72 polymorphism (c.215G&#x0003e;C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma</article-title><source>Hum Mutat</source><year>2004</year><volume>24</volume><fpage>21</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">15221786</pub-id><pub-id pub-id-type="doi">10.1002/humu.20055</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>TI</given-names></name><name><surname>Borresen</surname><given-names>AL</given-names></name><name><surname>Moller</surname><given-names>P</given-names></name></person-group><article-title>A common BRCA1 mutation in Norwegian breast and ovarian cancer families?</article-title><source>Am J Hum Genet</source><year>1996</year><volume>59</volume><fpage>486</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">8755943</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorum</surname><given-names>A</given-names></name><name><surname>Hovig</surname><given-names>E</given-names></name><name><surname>Trope</surname><given-names>C</given-names></name><name><surname>Inganas</surname><given-names>M</given-names></name><name><surname>Moller</surname><given-names>P</given-names></name></person-group><article-title>Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA</article-title><source>Eur J Cancer</source><year>1999</year><volume>35</volume><fpage>779</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">10505039</pub-id><pub-id pub-id-type="doi">10.1016/S0959-8049(99)00050-7</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Dorum</surname><given-names>A</given-names></name><name><surname>Heimdal</surname><given-names>K</given-names></name><name><surname>Maehle</surname><given-names>L</given-names></name><name><surname>Hovig</surname><given-names>E</given-names></name><name><surname>Moller</surname><given-names>P</given-names></name></person-group><article-title>BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations</article-title><source>Dis Markers</source><year>1999</year><volume>15</volume><fpage>79</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">10595257</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>SA</given-names></name><name><surname>Dykes</surname><given-names>DD</given-names></name><name><surname>Polesky</surname><given-names>HF</given-names></name></person-group><article-title>A simple salting out procedure for extracting DNA from human nucleated cells</article-title><source>Nucleic Acids Res</source><year>1988</year><volume>16</volume><fpage>1215</fpage><pub-id pub-id-type="pmid">3344216</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Vu</surname><given-names>P</given-names></name><name><surname>Lind</surname><given-names>GE</given-names></name><name><surname>Lothe</surname><given-names>R</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name></person-group><article-title>Mutation Screening of the TP53 Gene by Temporal Temperature Gradient Gel Electrophoresis</article-title><source>Methods Mol Biol</source><year>2004</year><volume>291</volume><fpage>207</fpage><lpage>216</lpage></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Eeles</surname><given-names>R</given-names></name><name><surname>Hollstein</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name><name><surname>Hainaut</surname><given-names>P</given-names></name></person-group><article-title>The IARC TP53 database: new online mutation analysis and recommendations to users</article-title><source>Hum Mutat</source><year>2002</year><volume>19</volume><fpage>607</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">12007217</pub-id><pub-id pub-id-type="doi">10.1002/humu.10081</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zweemer</surname><given-names>RP</given-names></name><name><surname>Shaw</surname><given-names>PA</given-names></name><name><surname>Verheijen</surname><given-names>RM</given-names></name><name><surname>Ryan</surname><given-names>A</given-names></name><name><surname>Berchuck</surname><given-names>A</given-names></name><name><surname>Ponder</surname><given-names>BA</given-names></name><name><surname>Risch</surname><given-names>H</given-names></name><name><surname>McLaughlin</surname><given-names>JR</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name><name><surname>Menko</surname><given-names>FH</given-names></name><name><surname>Kenemans</surname><given-names>P</given-names></name><name><surname>Jacobs</surname><given-names>IJ</given-names></name></person-group><article-title>Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations</article-title><source>J Clin Pathol</source><year>1999</year><volume>52</volume><fpage>372</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">10560359</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zweemer</surname><given-names>RP</given-names></name><name><surname>Verheijen</surname><given-names>RH</given-names></name><name><surname>Coebergh</surname><given-names>JW</given-names></name><name><surname>Jacobs</surname><given-names>IJ</given-names></name><name><surname>van Diest</surname><given-names>PJ</given-names></name><name><surname>Gille</surname><given-names>JJ</given-names></name><name><surname>Skates</surname><given-names>S</given-names></name><name><surname>Menko</surname><given-names>FH</given-names></name><name><surname>Ten Kate</surname><given-names>LP</given-names></name><name><surname>Kenemans</surname><given-names>P</given-names></name></person-group><article-title>Survival analysis in familial ovarian cancer, a case control study</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2001</year><volume>98</volume><fpage>219</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">11574135</pub-id><pub-id pub-id-type="doi">10.1016/S0301-2115(01)00318-9</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldgar</surname><given-names>DE</given-names></name><name><surname>Reilly</surname><given-names>PR</given-names></name></person-group><article-title>A common BRCA1 mutation in the Ashkenazim</article-title><source>Nat Genet</source><year>1995</year><volume>11</volume><fpage>113</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">7550331</pub-id><pub-id pub-id-type="doi">10.1038/ng1095-113</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Offman</surname><given-names>J</given-names></name><name><surname>Opelz</surname><given-names>G</given-names></name><name><surname>Doehler</surname><given-names>B</given-names></name><name><surname>Cummins</surname><given-names>D</given-names></name><name><surname>Halil</surname><given-names>O</given-names></name><name><surname>Banner</surname><given-names>NR</given-names></name><name><surname>Burke</surname><given-names>MM</given-names></name><name><surname>Sullivan</surname><given-names>D</given-names></name><name><surname>Macpherson</surname><given-names>P</given-names></name><name><surname>Karran</surname><given-names>P</given-names></name></person-group><article-title>Defective DNA Mismatch Repair in Acute Myeloid Leukemia/Myelodysplastic Syndrome After Organ Transplantation</article-title><source>Blood</source><year>2004</year><pub-id pub-id-type="pmid">15090454</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borresen</surname><given-names>AL</given-names></name><name><surname>Andersen</surname><given-names>TI</given-names></name><name><surname>Eyfjord</surname><given-names>JE</given-names></name><name><surname>Cornelis</surname><given-names>RS</given-names></name><name><surname>Thorlacius</surname><given-names>S</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Johansson</surname><given-names>U</given-names></name><name><surname>Theillet</surname><given-names>C</given-names></name><name><surname>Scherneck</surname><given-names>S</given-names></name><name><surname>Hartman</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains</article-title><source>Genes Chromosomes Cancer</source><year>1995</year><volume>14</volume><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">8527388</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buller</surname><given-names>RE</given-names></name><name><surname>Sood</surname><given-names>AK</given-names></name><name><surname>Lallas</surname><given-names>T</given-names></name><name><surname>Buekers</surname><given-names>T</given-names></name><name><surname>Skilling</surname><given-names>JS</given-names></name></person-group><article-title>Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer [see comments]</article-title><source>J Natl Cancer Inst</source><year>1999</year><volume>91</volume><fpage>339</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">10050867</pub-id><pub-id pub-id-type="doi">10.1093/jnci/91.4.339</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><collab>Bjorge T</collab><collab>Engeland A</collab><collab>Sundfor K</collab><name><surname>CG.</surname><given-names>T</given-names></name></person-group><article-title>Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital.</article-title><source>Acta Obstet Gynecol Scand</source><year>1998</year><volume>77</volume><fpage>777</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">9740528</pub-id><pub-id pub-id-type="doi">10.1034/j.1600-0412.1998.770714.x</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bjorge</surname><given-names>T</given-names></name><name><surname>Engeland</surname><given-names>A</given-names></name><name><surname>Hansen</surname><given-names>S</given-names></name><name><surname>Trope</surname><given-names>CG</given-names></name></person-group><article-title>Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993</article-title><source>Int J Cancer</source><year>1998</year><volume>75</volume><fpage>663</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">9495231</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19980302)75:5&#x0003c;663::AID-IJC1&#x0003e;3.0.CO;2-X</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Sporadic cases</td><td align="center" colspan="3"><italic>BRCA1 </italic>carriers</td></tr><tr><td></td><td></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td></td><td align="center">All familial cases</td><td align="center">1135insA</td><td align="center">1675delA</td></tr></thead><tbody><tr><td align="left">No of cases</td><td align="center">100</td><td align="center">30</td><td align="center">10</td><td align="center">20</td></tr><tr><td align="left">Age at diagnosis: Median</td><td align="center">59</td><td align="center">49</td><td align="center">52.5</td><td align="center">47</td></tr><tr><td align="center">range</td><td align="center">39 &#x02013; 80</td><td align="center">39 &#x02013; 80</td><td align="center">41 &#x02013; 80</td><td align="center">39 &#x02013; 65</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">FIGO stage</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02003;I &#x02013; II</td><td align="center">9 (9.0%)</td><td align="center">8 (26.7%)</td><td align="center">2 (20.0%)</td><td align="center">6 (30.0%)</td></tr><tr><td align="left">&#x02003;&#x02003;III</td><td align="center">65 (65.0%)</td><td align="center">14 (46.7%)</td><td align="center">5 (50.0%)</td><td align="center">9 (45.0%)</td></tr><tr><td align="left">&#x02003;&#x02003;IV</td><td align="center">26 (26.0%)</td><td align="center">8 (26.7%)</td><td align="center">3 (30.0%)</td><td align="center">5 (25.0%)</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">Histology</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02003;Serous</td><td align="center">82 (82.0%)</td><td align="center">24 (80.0%)</td><td align="center">7 (70.0%)</td><td align="center">17 (85.0%)</td></tr><tr><td align="left">&#x02003;&#x02003;Mixed</td><td align="center">7 (7.0%)</td><td align="center">2 (6.6%)</td><td align="center">1 (10.0%)</td><td align="center">1 (5.0%)</td></tr><tr><td align="left">&#x02003;&#x02003;Endometroid</td><td align="center">5 (5.0%)</td><td align="center">3 (10.0%)</td><td align="center">1 (10.0%)</td><td align="center">2 (10.0%)</td></tr><tr><td align="left">&#x02003;&#x02003;Unclassified</td><td align="center">6 (6.0%)</td><td align="center">1 (3.3%)</td><td align="center">1 (10.0%)</td><td align="center">0</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">Grade of differentiation</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02003;1</td><td align="center">7 (7.0%)</td><td align="center">0</td><td align="center">0</td><td align="center">0</td></tr><tr><td align="left">&#x02003;&#x02003;2</td><td align="center">26 (26.0%)</td><td align="center">5 (16.6%)</td><td align="center">1 (10.0%)</td><td align="center">4 (20.0%)</td></tr><tr><td align="left">&#x02003;&#x02003;3</td><td align="center">67 (67.0%)</td><td align="center">24 (80.0%)</td><td align="center">9 (90.0%)</td><td align="center">15 (75.0%)</td></tr><tr><td align="left">Unknown</td><td align="center">0</td><td align="center">1 (3.3%)</td><td align="center">0</td><td align="center">1 (5.0%)</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">Survival &#x0003e;5 years</td><td align="center">23 (23.0%)</td><td align="center">10 (33.3%)</td><td align="center">3 (30.0%)</td><td align="center">7 (35.0%)</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><italic>TP53 </italic>mutation status</td><td align="center">72.0%</td><td align="center">53.3%</td><td align="center">50.0%</td><td align="center">55.0%</td></tr></tbody></table><table-wrap-foot><p>All tumors are epithelial adenocarcinomas</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p><italic>TP53 </italic>mutations, survival and histopathological features for each case.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Case</td><td align="center"><sup>a</sup><italic>BRCA1 </italic>carrier type</td><td align="center">Stage</td><td align="center"><sup>b</sup>Grade</td><td align="center">Type</td><td align="center">TTGE</td><td align="center">Exon</td><td align="center">Codon</td><td align="center">Mutation</td><td align="center">aa change</td><td align="center">Age of diagnosis</td><td align="center"><sup>c</sup>Survival months</td><td align="center"><sup>d</sup>Vital status</td></tr></thead><tbody><tr><td align="center">3453</td><td align="center">1</td><td align="center">3</td><td align="center">2</td><td align="center">ser</td><td align="center">pos</td><td align="center">5</td><td></td><td align="center">559+1G&#x0003e;A</td><td align="center">splice</td><td align="center">53</td><td align="center">83</td><td align="center">1</td></tr><tr><td align="center"><bold>10</bold></td><td align="center">1</td><td align="center">3</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td align="center">6</td><td align="center">213</td><td align="center">CGA&#x0003e;TGA</td><td align="center">arg&#x0003e;stop</td><td align="center">65</td><td align="center">22</td><td align="center"><bold>3</bold></td></tr><tr><td align="center">2857</td><td align="center">1</td><td align="center">3</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td align="center">6</td><td align="center">213</td><td align="center">CGA&#x0003e;TGA</td><td align="center">arg&#x0003e;stop</td><td align="center">53</td><td align="center">83</td><td align="center">3</td></tr><tr><td align="center"><bold>4</bold></td><td align="center">1</td><td align="center">4</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td align="center">6</td><td align="center">216</td><td align="center">GTG&#x0003e;ATG</td><td align="center">val&#x0003e;met</td><td align="center">59</td><td align="center">11</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>27</bold></td><td align="center">1</td><td align="center">2</td><td align="center">3</td><td align="center">endo</td><td align="center">pos</td><td align="center">7</td><td align="center">237</td><td align="center">ATG&#x0003e;ATA</td><td align="center">met&#x0003e;ile</td><td align="center">39</td><td align="center">61</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>8<sup>e</sup></bold></td><td align="center">1</td><td align="center">3</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td align="center">7</td><td align="center">260</td><td align="center">TCC&#x0003e;TCT</td><td align="center">ser&#x0003e;ser</td><td align="center">49</td><td align="center">84</td><td align="center"><bold>3</bold></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">8</td><td align="center">306</td><td align="center">CGA&#x0003e;TGA</td><td align="center">arg&#x0003e;stop</td><td></td><td></td><td></td></tr><tr><td align="center"><bold>14</bold></td><td align="center">1</td><td align="center">1</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td align="center">8</td><td align="center">267</td><td align="center">CGG&#x0003e;CAG</td><td align="center">arg&#x0003e;gln</td><td align="center">51</td><td align="center">25</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>13</bold></td><td align="center">1</td><td align="center">4</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td align="center">8</td><td align="center">273</td><td align="center">CGT&#x0003e;AGT</td><td align="center">arg&#x0003e;ser</td><td align="center">39</td><td align="center">15</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>29</bold></td><td align="center">1</td><td align="center">3</td><td align="center">3</td><td align="center">mix</td><td align="center">pos</td><td align="center">8</td><td align="center">273</td><td align="center">CGT&#x0003e;TGT</td><td align="center">arg&#x0003e;cys</td><td align="center">50</td><td align="center">36</td><td align="center"><bold>3</bold></td></tr><tr><td align="center">2842</td><td align="center">1 1</td><td align="center">4</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td align="center">8</td><td align="center">273</td><td align="center">CGT&#x0003e;TGT</td><td align="center">arg&#x0003e;cys</td><td align="center">39</td><td align="center">35</td><td align="center">3</td></tr><tr><td align="center"><bold>21</bold></td><td align="center">1</td><td align="center">3</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td align="center">8</td><td align="center">293</td><td align="center">GGG&#x0003e;AGG</td><td align="center">gly&#x0003e;arg</td><td align="center">39</td><td align="center">21</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>26</bold></td><td align="center">1</td><td align="center">3</td><td align="center">2</td><td align="center">ser</td><td align="center">pos</td><td></td><td align="center">intron</td><td align="center">G&#x0003e;A</td><td align="center">ivs5</td><td align="center">53</td><td align="center">93</td><td align="center"><bold>1</bold></td></tr><tr><td align="center"><bold>9</bold></td><td align="center">1</td><td align="center">4</td><td align="center">2</td><td align="center">ser</td><td align="center">neg</td><td></td><td></td><td></td><td></td><td align="center">50</td><td align="center">39</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>11</bold></td><td align="center">1</td><td align="center">3</td><td align="center">3</td><td align="center">ser</td><td align="center">neg</td><td></td><td></td><td></td><td></td><td align="center">44</td><td align="center">8</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>17</bold></td><td align="center">1</td><td align="center">3</td><td align="center">3</td><td align="center">ser</td><td align="center">neg</td><td></td><td></td><td></td><td></td><td align="center">47</td><td align="center">30</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>24</bold></td><td align="center">1</td><td align="center">2</td><td align="center">4</td><td align="center">ser</td><td align="center">neg</td><td></td><td></td><td></td><td></td><td align="center">59</td><td align="center">20</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>34</bold></td><td align="center">1</td><td align="center">1</td><td align="center">3</td><td align="center">ser</td><td align="center">neg</td><td></td><td></td><td></td><td></td><td align="center">46</td><td align="center">120</td><td align="center"><bold>1</bold></td></tr><tr><td align="center"><bold>30</bold></td><td align="center">1</td><td align="center">1</td><td align="center">2</td><td align="center">ser</td><td align="center">neg</td><td></td><td></td><td></td><td></td><td align="center">43</td><td align="center">199</td><td align="center"><bold>2</bold></td></tr><tr><td align="center"><bold>32</bold></td><td align="center">1</td><td align="center">2</td><td align="center">3</td><td align="center">ser</td><td align="center">neg</td><td></td><td></td><td></td><td></td><td align="center">48</td><td align="center">108</td><td align="center"><bold>1</bold></td></tr><tr><td align="center"><bold>3351</bold></td><td align="center">1</td><td align="center">4</td><td align="center">3</td><td align="center">endo</td><td align="center">neg</td><td></td><td></td><td></td><td></td><td align="center">44</td><td align="center">9</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>1</bold></td><td align="center">2</td><td align="center">4</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td align="center">5</td><td align="center">144</td><td align="center">CAG&#x0003e;TAG</td><td align="center">gln&#x0003e;stop</td><td align="center">41</td><td align="center">1</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>3</bold></td><td align="center">2</td><td align="center">3</td><td align="center">3</td><td align="center">uncl</td><td align="center">pos</td><td align="center">6</td><td align="center">196</td><td align="center">CGA&#x0003e;TGA</td><td align="center">arg&#x0003e;stop</td><td align="center">48</td><td align="center">46</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>20</bold></td><td align="center">2</td><td align="center">3</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td align="center">6</td><td align="center">205</td><td align="center">TAT&#x0003e;TCT</td><td align="center">tyr&#x0003e;ser</td><td align="center">52</td><td align="center">36</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>28</bold></td><td align="center">2</td><td align="center">4</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td align="center">7</td><td align="center">261</td><td align="center">AGG&#x0003e;AGA</td><td align="center">arg&#x0003e;arg</td><td align="center">80</td><td align="center">12</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>7<sup>e</sup></bold></td><td align="center">2</td><td align="center">3</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td align="center">7</td><td align="center">255</td><td align="center">ATC&#x0003e;GTC</td><td align="center">ile&#x0003e;val</td><td align="center">58</td><td align="center">30</td><td align="center"><bold>3</bold></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">5</td><td align="center">141</td><td align="center">TGC&#x0003e;TGT</td><td align="center">cys&#x0003e;cys</td><td></td><td></td><td></td></tr><tr><td align="center"><bold>12</bold></td><td align="center">2</td><td align="center">1</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td align="center">8</td><td align="center">280</td><td align="center">AGA&#x0003e;GGA</td><td align="center">arg&#x0003e;gly</td><td align="center">49</td><td align="center">134</td><td align="center"><bold>1</bold></td></tr><tr><td align="center"><bold>15</bold></td><td align="center">2</td><td align="center">3</td><td align="center">3</td><td align="center">ser</td><td align="center">pos</td><td></td><td align="center">intron</td><td align="center">C&#x0003e;T</td><td align="center">ivs7</td><td align="center">50</td><td align="center">19</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>5</bold></td><td align="center">2</td><td align="center">4</td><td align="center">3</td><td align="center">ser</td><td align="center">neg</td><td></td><td></td><td></td><td></td><td align="center">60</td><td align="center">45</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>18</bold></td><td align="center">2</td><td align="center">2</td><td align="center">3</td><td align="center">endo</td><td align="center">neg</td><td></td><td></td><td></td><td></td><td align="center">44</td><td align="center">117</td><td align="center"><bold>3</bold></td></tr><tr><td align="center"><bold>22</bold></td><td align="center">2</td><td align="center">3</td><td align="center">2</td><td align="center">mix</td><td align="center">neg</td><td></td><td></td><td></td><td></td><td align="center">47</td><td align="center">96</td><td align="center"><bold>3</bold></td></tr></tbody></table><table-wrap-foot><p>a: 1 = 1675delA and 2 = 1135insA. b: undifferentiated (4). c: all patients were followed until diseased or to 15<sup>th </sup>April, 2004. d: alive without cancer (1), alive with cancer (2), and dead by cancer (3). e: two different mutations detected in sample.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Hazard risk of <italic>TP53 </italic>mutations on familial and sporadic ovarian cancer cases.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"># cases</td><td align="center">HR</td><td align="center">CI (95%)</td><td align="center">p-value</td></tr></thead><tbody><tr><td align="left">Familial Cases</td><td align="center">30</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02003;<italic>TP53 </italic>no mutation</td><td align="center">14</td><td align="center">1 (ref)</td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02003;<italic>TP53 </italic>mutation</td><td align="center">16</td><td align="center">1.64</td><td align="center">0.71 &#x02013; 3.78</td><td align="center">0.25</td></tr><tr><td align="left">Sporadic cases</td><td align="center">100</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02003;<italic>TP53 </italic>no mutation</td><td align="center">26</td><td align="center">1 (ref)</td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02003;<italic>TP53 </italic>mutation</td><td align="center">76</td><td align="center">0.96</td><td align="center">0.55 &#x02013; 1.66</td><td align="center">0.88</td></tr></tbody></table></table-wrap></sec></back></article> 